World's Best Scientists 2026 revealed!
Marc Bourlière

Marc Bourlière

D-Index & Metrics

Medicine

D-Index
84
Citations
29333
World Ranking
14985
National Ranking
482

Marc Bourlière publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Marc Bourlière sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 612 publications — 73rd percentile

73% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Marc Bourlière D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Marc Bourlière sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 84 D-Index — 27th percentile

27% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Marc Bourlière is affiliated with Hôpital Saint Joseph in France. Their research primarily focuses on medicine, with a concentration in hepatology and epidemiology. Their work also extends into surgery, infectious diseases, and oncology.

The scientist's research covers key topics such as liver disease diagnosis and treatment, hepatitis C virus research, hepatitis B virus studies, liver disease and transplantation, hepatocellular carcinoma treatment and prognosis, cholangiocarcinoma and gallbladder cancer studies, and liver diseases and immunity.

Marc Bourlière's frequent coauthors include Nathalie Ganne-Carrié, Victor de Lédinghen, Fabrice Carrat, Stanislas Pol, and Fabien Zoulim.

Their publications have appeared regularly in several prominent venues, including:

  • Journal of Hepatology
  • Clinics and Research in Hepatology and Gastroenterology
  • Liver International
  • Journal of Viral Hepatitis
  • JHEP Reports

Representative recent papers authored by or involving Marc Bourlière include:

  • "Advancing the global public health agenda for NAFLD: a consensus statement," 2021, Nature Reviews Gastroenterology & Hepatology
  • "Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials," 2020, Journal of Hepatology
  • "Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial," 2023, The Lancet
  • "Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial," 2023, The Lancet Oncology
  • "Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial," 2021, Nature Medicine

Best Publications

  • Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.

    Christophe Hézode;Nicole Forestier;Geoffrey Dusheiko;Peter Ferenci

  • Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening

    Vlad Ratziu;Vlad Ratziu;Stephen A. Harrison;Sven Francque;Pierre Bedossa

  • Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection

    Graham R. Foster;Nezam Afdhal;Stuart K. Roberts;Norbert Bräu

  • Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.

    Marion G. Peters;H. W. Hann;Paul Martin;E. Jenny Heathcote

  • Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection

    Marc Bourlière;Stuart C. Gordon;Steven L. Flamm;Curtis L. Cooper

  • Advancing the global public health agenda for NAFLD: a consensus statement.

    Jeffrey V Lazarus;Henry E Mark;Quentin M Anstee;Juan Pablo Arab

  • Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3

    Stefan Zeuzem;Rolf Hultcrantz;Marc Bourliere;Tobias Goeser

  • Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study

    Fabrice Carrat;Hélène Fontaine;Céline Dorival;Mélanie Simony

  • Clinical features and prognostic factors of listeriosis: the MONALISA national prospective cohort study.

    Caroline Charlier;Élodie Perrodeau;Alexandre Leclercq;Alexandre Leclercq;Benoît Cazenave

  • Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications

    Pierre Nahon;Pierre Nahon;Valérie Bourcier;Richard Layese;Etienne Audureau

  • Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C.

    John G. McHutchison;Geoffrey Dusheiko;Mitchell L. Shiffman;Maribel Rodriguez-Torres

  • Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890

    Christophe Hézode;Hélène Fontaine;Céline Dorival;Dominique Larrey

  • Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection

    Stefan Zeuzem;Graham R Foster;Stanley Wang;Armen Asatryan

  • Meta-analyses of FibroTest diagnostic value in chronic liver disease

    Thierry Poynard;Rachel Morra;Philippe Halfon;Laurent Castera

  • All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study

    Michael Peter Manns;Stanislas B Pol;Ira M Jacobson;Patrick M Marcellin

  • Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial

    Mark Sulkowski;Christophe Hezode;Jan Gerstoft;John M Vierling

  • Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

    Stephen A Harrison;Vincent Wai-Sun Wong;Takeshi Okanoue;Natalie Bzowej

  • Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS)

    Marc Bourlière;Jean Pierre Bronowicki;Victor de Ledinghen;Christophe Hézode

  • Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: The ANRS HCEP-23 study

    Jean-Pierre Zarski;Nathalie Sturm;Jérôme Guechot;Adeline Paris

  • Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients

    Stefan Zeuzem;Rolf Hultcrantz;Marc Bourliere;Tobias Goeser

Frequent Co-Authors

Jean-Pierre Bronowicki
Jean-Pierre Bronowicki University Hospital of Nancy
Philippe Halfon
Philippe Halfon Université Paris Cité
Stanislas Pol
Stanislas Pol Université Paris Cité
Dominique Larrey
Dominique Larrey University of Montpellier
Victor de Ledinghen
Victor de Ledinghen Grenoble Alpes University
Albert Tran
Albert Tran Inserm : Institut national de la santé et de la recherche médicale
Christophe Hézode
Christophe Hézode Université Paris Cité
Laurent Alric
Laurent Alric Federal University of Toulouse Midi-Pyrénées
Patrick Marcellin
Patrick Marcellin Université Paris Cité

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative healthcare career paths or online study options can offer flexibility and unique opportunities, especially for those interested in the medical field in the USA. For students who hold a non-nursing bachelor’s degree but wish to leverage their skills in the healthcare sector, direct entry msn programs for non-nursing majors online provide a streamlined transition into advanced nursing roles.

If you’re looking for accessible nursing pathways, direct entry nursing programs offer a chance to begin your nursing career even if your prior studies were in a different field. These programs are typically designed to fast-track your entry into the profession.

For those interested in administrative or support careers in healthcare, the best medical billing and coding schools online offer flexible study options, often with financial aid. These are suited for individuals who want a vital role in healthcare systems without direct patient care.

Finally, some accelerated nursing degrees, like absn programs that don't require teas, provide an alternative path for those who do not want to take standardized entrance exams, further expanding access to nursing careers.

Best Scientists Citing Marc Bourlière

Trending Scientists

Recently Published Articles